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Summary We report a male patient with a history of recur-
rent idiopathic vomiting, normal plasma ammonia and glu-
tamine concentrations in acute phase, who died at 3 years of
age. Ornithine transcarbamylase deficiency was diagnosed
after detecting elevated urinary orotate concentrations in a
sample collected just before death, and the diagnosis was
confirmed by DNA analysis.
Late-onset ornithine transcarbamylase (OTC; EC 2.1.3.3)
deficiency (McKusick 311250) is one of the most diffi-
cult urea cycle defects to recognize owing to the variety of
its clinical and biochemical signs (Brusilow and Horwich
2001).
In this report, we describe an Italian child, B.N., a second
twin, born at term from unrelated healthy parents. Among
the mother’s relatives, three siblings (one female and two
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male) are in good health. He was breast-fed for 6 months,
then breast feeding was stopped. He was poorly receptive to
formula feeding thereafter and suffered from recurrent vom-
iting. Weight and height were normal during the first year of
life. At 15 months of age, he was referred to a tertiary hospital
after a day of persistent vomiting and somnolence alternating
with periods of irritability. Weight was at 75th centile (12 kg).
According to his parents, the child had no aversion to pro-
teins (daily intake 2.5 g/kg) and the episodes seemed to be
more related to fructose ingestion. Mild hepatomegaly was
present and the electroencephalogram showed bilateral slow
activity. Routine biochemical investigations showed elevated
transaminases (AST 300 U/L, ALT 1727 U/L) but normal
ammonia (40 μmol/L; normal values 35–75), lactate, plasma
amino acids (Table 1) and acylcarnitine profile by tandem
MS. Serology for hepatitis viruses A, B and C was negative.
The clinical signs disappeared spontaneously after glucose
infusion over the next 24 h.
To confirm suspected fructosaemia, the patient was eval-
uated in our Unit. Physical examination revealed normal
growth (weight and height at 50th centile); however, the
weight had increased only slowly in the previous 3 months;
the liver was palpable one finger-breadth below the right
costal margin. The laboratory findings on the morning of
admission showed normal ammonia, plasma amino acids and
urinary organic acids (orotate 1.2 mmol/mol creatinine, nor-
mal values <2.5; and uracil 54 mmol/mol creatinine, normal
values <64.5). Serum transferrin (Tf) analysis by capillary
zone electrophoresis showed an increased trisialo-Tf form,
suggesting a possible diagnosis of fructosaemia. The patient
was put on a low-fructose diet and molecular analysis for
aldolase B gene mutation was performed.
About 4 months later, he was readmitted to the local
hospital with severe acute encephalopathy after a day of
continuous vomiting. Brain CT scan showed severe oedema.
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Table 1 Plasma amino acid
profiles in stable clinical
conditions and during
encephalopathic crisis
Normal status Acute crisisa Normal valuesb
Amino acid (μmol/L) (μmol/L) (μmol/L)
Phenylalanine 88 230 26–91
Tyrosine 74 98 24–115
Methionine 29 52 4–47
Leucine 154 202 49–216
Isoleucine 66 94 22–107
Histidine 101 117 41–125
Valine 284 319 74–321
Threonine 102 97 35–226
Arginine 99 106 10–140
Lysine 125 157 48–284
Ornithine 66 45 10–163
Proline 185 243 59–369
Glutamate 100 169 5–150
Glutamine 721 621 254–823
γ-Aminobutyrate 22 26 4–31
Glycine 202 217 127–341
Taurine 95 117 10–170
Serine 151 197 69–187
Alanine 369 456 152–547
Aspartate 10 63 1–24
Asparagine 55 47 23–112
Citrulline 15 22 8–46
aSample collected just before
death
bModifed from Shih VE (2003)
In: Blau N, Duran M,
Blaskovics ME, Gibson KM,
eds. Physician’s Guide to the
Laboratory Diagnosis of
Metabolic Diseases. New York:
Springer
Liver transaminases were increased (AST 557 U/L, ALT
1923 U/L); ammonia, which was monitored closely, was
initially normal and only reached a value of 120 μmol/L at
the end stage; plasma amino acids (Table 1) were normal.
Despite treatment with hyperosmolar agents, the child died
the following morning. Urinary organic acids collected
before his death showed peaks of orotic acid and uracil (270
and 685 mmol/mol creatinine, respectively), suggesting an
OTC deficiency. OTC gene analysis disclosed a missense
mutation in exon 3, containing an adenine-to-thymine
transversion (base 264), changing codon 88 from lysine to
asparagine. The mother and second twin were found to carry
no such mutation.
Discussion
This observation emphasizes the great heterogeneity of clin-
ical and biochemical signs of OTC deficiency, which can
pose considerable diagnostic difficulties not only in the de-
tection of carriers but also in late-onset presentations in males
(Steiner and Cederbaum 2001).
In this patient, ammonia and amino acid assays, which
play a pivotal part in the diagnosis of OTC deficiency, were
performed either during the acute phase (the day after the
glucose infusion) or during the metabolic assessment a month
after the acute episode, when we decided that an allopurinol
challenge test was unnecessary given that all the metabolic
parameters, including urinary orotic acid, were normal. The
urinary organic acid analysis performed in the last sample
collected before the child’s death unexpectedly showed an
increase in orotic acid and orotidine concentrations, as well
as in uracil. Surprisingly, the plasma sample collected at the
same time showed only mildly raised ammonia and no plasma
amino acid abnormalities.
It has been reported that plasma ammonia concentrations
can be normal in OTC patients as a consequence of the pro-
tein intake (Spada et al 1994). Oddly, plasma glutamine was
also normal, even in the acute stage. We can offer no clear
explanation for such an unusual finding at present. Similar
biochemical findings had already been reported in an 8-year-
old Italian boy with recurrent episodes of bizarre behaviour
and an unremarkable metabolic work-up (Spada et al 1994).
A diagnosis of OTC was ultimately reached after a one-day
high-protein diet and subsequent orotic acid assay in the pa-
tient’s urine.
Despite his normal plasma glutamine levels, our patient
developed a severe cerebral oedema. It is well known that
brain oedema is a characteristic and often terminal symptom
in urea cycle disorders. The brain oedema in OTC deficiency
may be due to the swelling of astrocytes, in which glutamine
may have a role (Bachmann 2002), a cytotoxic oedema with
cell swelling, and a reduction in extracellular space.
As for the molecular analysis, our findings are as intrigu-
ing as the biochemical features. The patient had a muta-
tion in codon 88, exon 3, resulting in the substitution of
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asparagine for lysine two codons upstream from the putative
carbamyl phosphate binding site coding domain. This rare
mutation has been reported in patients with a mild, late-
onset presentation (Reish et al 1993). Furthermore, it has
been suggested that such a mutation does not completely
abolish OTC activity (McCullogh et al 2000). To our knowl-
edge, ours is the first reported case of a male patient with
OTC deficiency presenting such a complex and dramatic
clinical picture, with plasma ammonia and glutamine lev-
els remaining constantly normal even during acute metabolic
decompensation.
In conclusion, the diagnosis of OTC deficiency has to be
considered when a child has recurrent idiopathic vomiting
with neurological signs despite normal ammonia and plasma
glutamine in the acute phase.
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